Amicus

For information visit amicusrx.com

Amicus Therapeutics and the University of Pennsylvania Announce Major Expansion of Gene Therapy Collaboration

Amicus Therapeutics, is pleased to share with the NNPDF, an update on their gene therapy research and development endeavors. This morning, Amicus Therapeutics and the Gene Therapy Program (GTP) in the Perelman School of Medicine at the University of Pennsylvania announced the expansion of their ongoing gene therapy research and development collaboration, adding the lysosomal disorders of Niemann-Pick Type C.

CLICK HERE FOR COMPLETE ANNOUNCEMENT

05/29/2019 jjb

The National Niemann-Pick Disease Foundation (NNPDF) does not engage in the practice of medicine. It is not a medical authority nor does it claim to have medical knowledge. This site is an educational service of the National Niemann-Pick Disease Foundation and is not meant to provide diagnostic or treatment advice. Information contained or suggested on this Web site does not constitute medical advice. For all information related to care, medication or treatment, the NNPDF recommends consulting a physician to determine if information presented is applicable. Please review these additional cautions about medical information provided on the Internet.

This Web site is a service of the National Niemann-Pick Disease Foundation's Family Services Program, made possible by the financial support of our member families and other generous donors and grantors. This site receives no government funding, nor does it host or receive funding from advertising or from the display of commercial content.

The National Niemann-Pick Disease Foundation is a 501(c)(3) organization. Your donations are fully tax-deductible.

Amicus

Amicus Therapeutics and the University of Pennsylvania Announce Major Expansion of Gene Therapy Collaboration

05/29/2019 jjb

Share this!